Mammo 2026: OncoDaily and Olema Pharmaceuticals Bring Global Breast Cancer Perspectives Together
OncoDaily and Olema Pharmaceuticals are collaborating for Mammo 2026, a virtual global congress on breast cancer care taking place on October 8-9, 2026. Olema Oncology is a Bronze Sponsor, supporting the international scientific program that will cover the full breast cancer continuum, from screening to survivorship. The congress aims to bring together global experts to discuss advances, challenges, and evolving priorities in breast cancer prevention, diagnosis, treatment, and research.
Bank of America Corp DE Makes New Investment in Olema Pharmaceuticals, Inc. $OLMA
Bank of America Corp DE has acquired a new stake of 334,875 shares, valued at approximately $4.19 million, in Olema Pharmaceuticals Inc. during the second quarter of 2026. This investment makes Bank of America Corp DE an owner of 0.38% of Olema Pharmaceuticals, a clinical-stage biopharmaceutical company. Despite a recent quarterly loss of $0.61 per share and a significant drop from its 52-week high, institutional investors collectively own 91.78% of OLMA, and analysts maintain a "Moderate Buy" rating with an average price target of $40.60.
Olema Pharmaceuticals (NASDAQ:OLMA) Shares Down 7.1% - Time to Sell?
Olema Pharmaceuticals (NASDAQ:OLMA) experienced a 7.1% drop in shares, trading at $8.95 with significantly reduced volume. Despite several analyst price target cuts, the stock maintains a "Moderate Buy" consensus with an average target of $40.60. The decline follows the company missing its latest quarterly earnings estimate, reporting a loss of $0.61 per share against an expected $0.55 loss.
H.C. Wainwright Maintains Olema Pharmaceuticals(OLMA.US) With Buy Rating, Maintains Target Price $36
H.C. Wainwright has reaffirmed its Buy rating for Olema Pharmaceuticals (OLMA.US) and maintained its target price at $36. This indicates continued confidence from the analyst firm in the company's prospects.
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Receives Average Rating of "Moderate Buy" from Analysts
Olema Pharmaceuticals (NASDAQ:OLMA) has received a consensus "Moderate Buy" rating from thirteen analysts, with an average 12-month price target of $40.60. Despite some recent price target adjustments by JPMorgan and Stifel, and a reiterated buy rating from Citigroup, the company reported a quarterly loss of $0.61 per share, missing estimates. Institutional investors hold approximately 91.78% of the shares, while one director recently sold 12,500 shares.
A Quick Look at Today's Ratings for Olema Pharmaceuticals(OLMA.US), With a Forecast Between $16 to $59
This article provides a quick look at analyst ratings for Olema Pharmaceuticals (OLMA.US), presenting a forecast range between $16 and $59. It is based on a document and implies a review of current market sentiment and price targets for the company.
Olema Pharmaceuticals Shares Fall 15.1% Following AstraZeneca SERENA-4 Trial Results
Olema Pharmaceuticals shares dropped 15.1% in pre-market trading after AstraZeneca's Phase 3 SERENA-4 trial for camizestrant failed to meet its primary endpoint in treating ER-positive, HER2-negative advanced breast cancer. Investors are assessing these results for their potential implications on Olema's lead candidate, palazestrant, which has a similar mechanism and is currently in its own Phase 3 trial. Following this news, Stifel reduced Olema's price target, although it maintained a Buy rating, as the market awaits specific clinical data from Olema's OPERA-01 trial.
Citi Maintains Olema Pharmaceuticals(OLMA.US) With Buy Rating, Maintains Target Price $59
Citi has reiterated its Buy rating for Olema Pharmaceuticals (OLMA.US) and maintained its target price at $59. This indicates a continued positive outlook from the firm regarding the company's stock performance.
Olema Pharmaceuticals (NASDAQ:OLMA) Shares Down 4.4% - Here's Why
Olema Pharmaceuticals (OLMA) shares dropped 4.4% in mid-day trading on Friday, with trading volume significantly lower than average. This decline occurred despite analysts maintaining a "Moderate Buy" consensus rating and an average price target of $42.40, though several price targets have been reduced. The company recently missed its quarterly earnings expectations, reporting a wider loss than anticipated.
Olema Pharmaceuticals, Inc. $OLMA Shares Sold by Squarepoint Ops LLC
Squarepoint Ops LLC reduced its stake in Olema Pharmaceuticals (OLMA) by 28.3% in the second quarter, selling 243,082 shares, though institutional investors still hold 91.78% of the company. Olema reported a Q2 loss of $0.61 per share, missing analyst estimates, with a full-year loss of $2.43 per share anticipated. Despite several recent price target reductions, analysts maintain a "Moderate Buy" rating with an average target of $42.40 for the stock, which currently trades at $10.69.
Olema Pharmaceuticals (NASDAQ:OLMA) Shares Up 3.5% - Should You Buy?
Olema Pharmaceuticals (NASDAQ:OLMA) saw its shares rise by 3.5% to about $10.73, despite a significant 92% drop in trading volume compared to its daily average. The clinical-stage cancer-drug developer, currently in Phase 3 trials for its lead candidate OP-1250 for advanced breast cancer, maintains a "Moderate Buy" consensus rating from analysts with an average target price of $42.40, even after recent price target cuts and missing its latest quarterly EPS estimate. Insider selling and institutional investment adjustments were also noted.
Wellington Management Group LLP Cuts Holdings in Olema Pharmaceuticals, Inc. $OLMA
Wellington Management Group LLP reduced its stake in Olema Pharmaceuticals (NASDAQ:OLMA) by 20.8% in the second quarter, selling 138,233 shares and retaining 526,446 shares valued at $6.6 million. Institutional investors collectively own 91.78% of OLMA, and analysts maintain a "Moderate Buy" consensus with an average price target of $42.40, despite several recent target reductions. The company's stock opened at $10.98, significantly below its 52-week high, and it reported a wider-than-expected quarterly loss of $0.61 per share.
Readystate Asset Management LP Makes New Investment in Olema Pharmaceuticals, Inc. $OLMA
Readystate Asset Management LP has acquired a new stake in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA), purchasing 593,829 shares valued at approximately $7.4 million, representing a 0.68% ownership. This move comes as institutional investors collectively hold a significant 91.78% of the company's stock, despite several analysts lowering price targets for the biotech firm, which is currently conducting Phase 3 trials for a breast cancer treatment.
Bank of New York Mellon Corp Invests $2.78 Million in Olema Pharmaceuticals, Inc. $OLMA
Bank of New York Mellon Corp has acquired a new stake of 222,177 shares in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) worth approximately $2.78 million. Other institutional investors have also adjusted their holdings, with institutional ownership now at 91.78%. Despite analysts maintaining a "Moderate Buy" rating with a $42.40 price target, the company recently missed earnings estimates and a director sold shares.
Olema Pharmaceuticals (NASDAQ: OLMA) grants CFO 650K options expiring in 2036
Olema Pharmaceuticals' Chief Financial Officer, Jason O'Byrne, was granted 650,000 stock options on September 1, 2026, with an exercise price of $10.56 per share and an expiration date of August 31, 2036. The options have a vesting schedule where 25% vest on August 11, 2027, and the remainder vest monthly over the subsequent 36 months, contingent on his continued service. This grant was reported in a Form 4 filing, indicating it was an award rather than a purchase and was not tied to a Rule 10b5-1 trading plan.
Olema Pharmaceuticals Grants Inducement Stock Options to Newly Appointed CFO Jason V. O’Byrne
Olema Pharmaceuticals has appointed Jason V. O’Byrne as its new Chief Financial Officer, effective August 11, 2026. In connection with this appointment, he was granted an employment inducement award of 650,000 stock options with an exercise price of $10.56 per share, vesting over four years. This move is intended to align his interests with shareholders and strengthen the company's financial leadership as it continues to develop breast cancer treatments.
A new finance chief gets options on 650,000 Olema shares
Olema Oncology (OLMA) has granted its new Chief Financial Officer, Jason V. O’Byrne, 650,000 stock options as an employment inducement award. The options, issued on September 1, 2026, have an exercise price of $10.56 per share and vest over four years, conditional on continuous employment. This grant is in accordance with Nasdaq Listing Rule 5635(c)(4).
BlackRock Inc. Makes New Investment in Olema Pharmaceuticals, Inc. $OLMA
BlackRock Inc. has acquired a new position in Olema Pharmaceuticals (NASDAQ:OLMA), purchasing 6.7 million shares valued at approximately $84 million, which represents a 7.69% stake in the company. Institutional investors now own 91.78% of OLMA. Despite several recent price target reductions, analysts maintain a "Moderate Buy" rating with an average price target of $42.40.
Olema Oncology Reports Second Quarter 2026 Financial and Operating Results
Olema Oncology reported its second quarter 2026 financial and operating results, highlighting the completion of enrollment in its pivotal Phase 3 OPERA-01 trial for palazestrant, with top-line data expected in Q1 2027. The company also presented initial Phase 1 clinical data for OP-3136, showing anti-tumor activity, and announced a collaboration with Bayer for a clinical trial combining OP-3136 with darolutamide. Olema ended the quarter with $461.1 million in cash, cash equivalents, and marketable securities, with a net loss of $63.2 million reflecting increased investment in clinical development.
Jupiter Topco LLC Takes $88.80 Million Position in Olema Pharmaceuticals, Inc. $OLMA
Jupiter Topco LLC has acquired a significant new position in Olema Pharmaceuticals (NASDAQ:OLMA), purchasing 7.09 million shares valued at $88.8 million, representing 8.11% of the company. Despite institutional investors owning a large percentage of the stock and a "Moderate Buy" consensus rating with an average price target of $42.40, the company recently reported a quarterly loss exceeding analyst expectations and has seen some target price reductions. Shares of Olema Pharmaceuticals are currently trading around $10.85, with insiders also making recent stock sales.
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Given Consensus Rating of "Moderate Buy" by Brokerages
Olema Pharmaceuticals (NASDAQ:OLMA) has received a consensus "Moderate Buy" rating from fourteen brokerages, with an average 12-month price target of $42.40 despite recent target reductions from several firms. The stock has experienced a sharp decline, opening at $10.43, and the company reported a quarterly EPS loss of $0.61, missing analyst expectations. Institutional investors hold a significant 91.78% of the shares, while an insider recently sold 12,500 shares.
J.P. Morgan Maintains Olema Pharmaceuticals(OLMA.US) With Buy Rating, Maintains Target Price $46
J.P. Morgan has reiterated its Buy rating on Olema Pharmaceuticals (OLMA.US) and maintained a target price of $46. This continued positive outlook from the financial institution suggests confidence in the company's future performance. The maintained target price indicates that J.P. Morgan analysts believe the stock has significant upside potential from its current trading levels.
Olema Oncology Appoints Jason O’Byrne as Chief Financial Officer
Olema Oncology has appointed Jason O’Byrne, MBA, as its new Chief Financial Officer, leveraging his two decades of finance and global operations leadership experience. His appointment comes at a crucial time as the company approaches pivotal data from its OPERA-01 trial and prepares for a potential commercial launch. O'Byrne will play a key role in transforming Olema into a fully integrated oncology company, focusing on corporate strategy, capital markets, and financial management.
J.P. Morgan Maintains Olema Pharmaceuticals(OLMA.US) With Buy Rating, Announces Target Price $46
J.P. Morgan has reiterated its Buy rating on Olema Pharmaceuticals (OLMA.US) and set a price target of $46. This indicates a positive outlook from the firm regarding the company's future performance.
Form 8K Olema Pharmaceuticals Inc For: 13 August By Investing.com
This article from Investing.com reports on an SEC Form 8-K filing by Olema Pharmaceuticals Inc. for August 13th. The content is brief, primarily serving as an announcement of the filing rather than providing detailed analysis. The article includes standard financial market data and popular news links, but the core information is the Form 8-K disclosure.
Form 8K Olema Pharmaceuticals Inc For: 13 August By Investing.com
This article announces the filing of a Form 8K by Olema Pharmaceuticals Inc. on August 13. It includes the stock symbol OLMA and indicates a slight negative change in its price. The content provides a general news format from Investing.com with market data and related articles.
Olema Oncology Appoints Jason O’Byrne as Chief Financial Officer
Olema Pharmaceuticals, Inc. (Olema Oncology) has appointed Jason O’Byrne, MBA, as its new Chief Financial Officer. O'Byrne brings over two decades of finance and operations leadership from high-growth biotechnology and pharmaceutical organizations, including roles at Vir Biotechnology, Caribou Biosciences, Audentes Therapeutics, and Genentech/Roche. His appointment comes at a crucial time as Olema approaches pivotal data from OPERA-01 and prepares for a potential first commercial launch, aiming to transform into a fully integrated oncology company.
Olema Oncology’s New CFO Brings More Than Two Decades in Biotech
Olema Oncology (Nasdaq: OLMA) has appointed Jason O’Byrne as its new Chief Financial Officer, bringing over two decades of finance leadership experience in the biotech and pharmaceutical sectors. This appointment comes as the company approaches pivotal data from its OPERA-01 study and prepares for its first potential commercial launch. O’Byrne's extensive background in capital markets, M&A integration, and financial operations is expected to support Olema's transformation into a fully integrated oncology company.
Olema Pharmaceuticals Stock Falls as Pivotal Breast Cancer Data Pushed Into 2027
Olema Pharmaceuticals' stock fell by 12.90% after the company announced that pivotal breast cancer data for its Phase 3 OPERA-01 trial would be delayed until the first quarter of 2027. Despite this setback, the company presented initial Phase 1 data for OP-3136, showing its continued development in women's cancer therapies. Analysts maintain a "Buy" rating with an average price forecast of $43.00, though some have lowered their individual forecasts.
Olema Pharmaceuticals Stock Falls as Pivotal Breast Cancer Data Pushed Into 2027
Olema Pharmaceuticals' stock fell after announcing that top-line data for its pivotal Phase 3 OPERA-01 trial for breast cancer is now expected in Q1 2027, a delay from previous expectations. The company also reported a net loss of $63.2 million for Q2 2026, an increase from the previous year, attributed to higher spending on clinical development. Despite a "Buy" consensus from analysts, the stock is showing bearish technical indicators.
Olema Oncology Reports Second Quarter 2026 Financial and Operating Results
Olema Oncology reported its financial and operating results for the second quarter ended June 30, 2026, highlighting the completion of enrollment in its pivotal Phase 3 OPERA-01 trial for palazestrant, with top-line data expected in Q1 2027. The company also presented initial Phase 1 clinical data for OP-3136, showing anti-tumor activity, and announced a collaboration with Bayer to evaluate OP-3136 in metastatic castration-resistant prostate cancer. Olema ended the quarter with $461.1 million in cash, cash equivalents, and marketable securities, while reporting a net loss of $63.2 million, an increase from the prior year, primarily due to higher R&D and G&A expenses supporting late-stage clinical trials.
Olema Pharmaceuticals (NASDAQ:OLMA) Price Target Lowered to $59.00 at Citigroup
Citigroup has lowered its price target for Olema Pharmaceuticals (NASDAQ:OLMA) to $59.00 but maintained a "buy" rating, indicating a significant potential upside. This adjustment comes as the company reported a larger-than-expected quarterly loss of $0.61 per share. Olema Pharmaceuticals is a clinical-stage biotech focusing on treatments for women's cancers, with institutional investors holding a substantial stake in the company.
Olema Pharmaceuticals (NASDAQ:OLMA) Shares Gap Down on Disappointing Earnings
Olema Pharmaceuticals (NASDAQ:OLMA) gapped down after reporting Q2 EPS of $(0.61), missing analyst estimates. Despite the disappointing earnings, analyst sentiment remains largely positive with a "Moderate Buy" consensus rating and a $43.90 target price. Institutional investors hold a significant portion of the stock, while insider selling by Director Cyrus Harmon was noted.
TD Cowen Maintains Olema Pharmaceuticals(OLMA.US) With Buy Rating
TD Cowen analyst Tyler Van Buren has reiterated a Buy rating on Olema Pharmaceuticals (OLMA.US). Van Buren has a 63.4% success rate and an average return of 38.8% over the past year, according to TipRanks data. The article emphasizes that this information is for informational purposes only and not an investment recommendation.
Olema Pharmaceuticals, Inc. Stock 12‑Month Price Target Cut to $39.9, Implies 234% Upside
Olema Pharmaceuticals, Inc.'s average 12-month price target has been adjusted to $39.9, down from $40.7, according to estimates from 10 analysts. This new target suggests a potential upside of approximately 234% based on the August 10 closing price. The consensus rating from 11 analysts remains a "Buy" with no "Holds" or "Sells."
Olema Pharmaceuticals, Inc. Stock 12‑Month Price Target Cut to $40.1, Implies 236% Upside
Olema Pharmaceuticals, Inc. (OLMA) has seen its average 12-month price target adjusted to $40.1 by analysts, down from $40.7, implying a 236% potential upside from its current closing price. The consensus rating from 11 analysts remains a "Buy," with no "Hold" or "Sell" recommendations.
Olema Pharmaceuticals falls 6% on second quarter EPS miss
Olema Pharmaceuticals (NASDAQ:OLMA) reported a second-quarter loss of $0.61 per share, missing analyst estimates by $0.06, leading to a 5.8% stock decline. The company's net loss increased to $63.2 million due to higher spending on clinical development for breast cancer therapies palazestrant and OP-3136. Olema completed enrollment for its pivotal Phase 3 OPERA-01 trial, with top-line data expected in Q1 2027, and announced a collaboration with Bayer for OP-3136 in prostate cancer.
Olema Pharmaceuticals Q2 Loss Widens
NULL
Olema Oncology Reports Second Quarter 2026 Financial and Operating Results
Olema Oncology announced its financial and operating results for the second quarter of 2026, highlighting the completion of enrollment in its pivotal Phase 3 OPERA-01 trial with top-line data expected in Q1 2027. The company also reported initial Phase 1 clinical data for OP-3136, showing anti-tumor activity and good tolerability, and a new collaboration with Bayer. Olema ended the quarter with $461.1 million in cash, cash equivalents, and marketable securities, with a net loss of $63.2 million due to increased R&D and G&A expenses for advancing clinical trials.
Olema Pharmaceuticals Q2 Results: EPS misses estimates, losses widen
Olema Pharmaceuticals reported a Q2 EPS of $(0.61), missing the analyst consensus of $(0.55) by 10.91%. This represents a 19.61% increase in losses year-over-year from $(0.51), indicating persistent profitability challenges. The company's financial trajectory suggests a disconnect between market expectations and its current performance, with the reasons for widening losses remaining unclear without further revenue or margin data.
Earnings Flash (OLMA) Olema Pharmaceuticals Posts Q2 Loss per Share $0.61, vs. FactSet Est of $0.55 Loss
Olema Pharmaceuticals (OLMA) reported a Q2 loss per share of $0.61, which is wider than the FactSet estimated loss of $0.55 per share. The company is a clinical-stage biopharmaceutical company focused on breast cancer treatments. The article also mentions recent news regarding their clinical trial collaborations and inclusion in Russell indices.
Olema Pharmaceuticals (NASDAQ:OLMA) Releases Earnings Results, Misses Estimates By $0.08 EPS
Olema Pharmaceuticals (NASDAQ:OLMA) reported a quarterly loss of $0.61 per share, missing analysts' consensus estimate by $0.08. The company's stock traded down to $11.94, with a market capitalization of $1.04 billion. Despite missing estimates, Wall Street analysts maintain a "Moderate Buy" consensus rating with an average price target of $44.10.
Olema Pharmaceuticals falls 6% on second quarter EPS miss
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) reported a wider-than-expected second-quarter loss of $0.61 per share, missing analyst estimates. This news led to a 5.8% drop in its stock during after-hours trading. The increased net loss of $63.2 million was attributed to higher spending on clinical development and research activities for its breast cancer therapies, palazestrant and OP-3136.
Olema Oncology Reports Second Quarter 2026 Financial and Operating Results
Olema Oncology reported its financial and operating results for the second quarter ended June 30, 2026, highlighting the completion of enrollment in the pivotal Phase 3 OPERA-01 trial with top-line data expected in Q1 2027. The company also presented initial Phase 1 clinical data for OP-3136, showing it was well-tolerated with anti-tumor activity, and announced a collaboration with Bayer to evaluate OP-3136 in metastatic castration-resistant prostate cancer. Olema ended the quarter with $461.1 million in cash and reported a net loss of $63.2 million.
Olema Pharmaceuticals Q2 Loss Widens
Olema Pharmaceuticals (OLMA) reported a widening net loss of $0.61 per diluted share for the second quarter. The full details of this report are available to subscribers of Yahoo Finance Gold or other premium plans.
Olema Pharmaceuticals earnings up next ahead of key trial data
Olema Pharmaceuticals is set to report its second-quarter results, with analysts expecting wider losses as the clinical-stage biotech continues to advance its breast cancer pipeline. Investors are keenly awaiting top-line data from its Phase 3 OPERA-01 trial, expected this fall, which will be crucial for validating its lead drug palazestrant. The company also announced a collaboration with Bayer for its OP-3136 candidate, expanding its potential beyond breast cancer.
Dimensional Fund Advisors LP Acquires 123,790 Shares of Olema Pharmaceuticals, Inc. $OLMA
Dimensional Fund Advisors LP increased its stake in Olema Pharmaceuticals (NASDAQ:OLMA) by 12.9%, acquiring an additional 123,790 shares to bring its total holding to 1.08 million shares, valued at $16.1 million. Institutional ownership of OLMA remains high at 91.78%, with several other firms also initiating or expanding positions. Analysts generally rate OLMA as a "Moderate Buy" with an average price target of $44.10, despite the stock trading around $12.05 and the company currently being unprofitable.
FMR LLC, Abigail Johnson disclose 13.8% Olema Pharmaceuticals (OLMA) ownership
FMR LLC and Abigail P. Johnson have disclosed a 13.8% beneficial ownership stake in Olema Pharmaceuticals Inc. (OLMA) through an Amendment No. 2 to a Schedule 13G filing. This represents 12,075,061.72 shares as of June 30, 2026. FMR LLC holds sole voting power over 12,074,535 shares and both FMR LLC and Abigail Johnson hold sole dispositive power over 12,075,061.72 shares.
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Olema Pharmaceuticals, Inc. (Olema Oncology) announced that it granted stock options to seven new employees to purchase an aggregate of 254,540 shares of the Company's common stock. These grants, effective August 3, 2026, were made under Olema's 2022 Inducement Plan as an inducement for employment, in compliance with Nasdaq Listing Rule 5635(c)(4). The stock options have a 10-year term, an exercise price of $11.28 per share, and vest over four years.
Have Olema Pharmaceuticals Insiders Been Selling Stock?
Olema Pharmaceuticals has seen recent insider selling, including a notable divestment by an Independent Director and a larger sale by the Chief Medical Officer last year. While the CMO's sale was at a higher price than current stock, overall insider ownership is modest at 2.7%, and there have been no insider purchases in the last year, leading to caution regarding the stock.
